Steve Brozak
Stock Analyst at WBB Securities
(1.92)
# 3,359
Out of 5,030 analysts
14
Total ratings
42.86%
Success rate
5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Reiterates: Strong Buy | $45 | $8.11 | +455.21% | 3 | Oct 15, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Strong Buy | $123 → $199 | $101.52 | +96.02% | 5 | Oct 9, 2025 | |
| CELU Celularity | Upgrades: Buy | $6 | $1.98 | +203.03% | 2 | Sep 9, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.02 | +1,125.49% | 1 | Apr 1, 2025 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $1.50 | +1,066,566.67% | 3 | May 28, 2021 |
Omeros
Oct 15, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $8.11
Upside: +455.21%
Cidara Therapeutics
Oct 9, 2025
Maintains: Strong Buy
Price Target: $123 → $199
Current: $101.52
Upside: +96.02%
Celularity
Sep 9, 2025
Upgrades: Buy
Price Target: $6
Current: $1.98
Upside: +203.03%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.02
Upside: +1,125.49%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $1.50
Upside: +1,066,566.67%